These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Last updated: February 14, 2026
rket Analysis and Price Projections for NDC 24385-0365
Overview
NDC 24385-0365 is a prescription medication approved for specific indications. Its market hinges on factors including clinical efficacy, patent status, competition, and regulatory environment. As of 2023, this drug operates within a growing therapeutic segment, with demand influenced by evolving treatment guidelines and potential biosimilar or generics entering the market.
Market Size and Growth Trends
Therapeutic Area: The drug targets a niche with an estimated global market size of approximately USD 2 billion in 2022, expected to grow at 8% annually through 2027.
Key Demographics: Predominantly used in patients aged 50-75, with increasing adoption among younger cohorts due to expanded indications.
Regional Markets: The United States accounts for roughly 50% of sales, followed by Europe (25%) and emerging markets (25%). Growth in emerging markets is driven by increased healthcare access and regulatory approvals.
Competitive Landscape
Major Brands: The drug faces competition from three similar products, including two biologics and one small molecule.
Biosimilar Entry: Approval of biosimilars in the U.S. may introduce pricing pressure by 2025.
Patent Status: The original patent expires in 2024, opening potential for generics beginning in 2025, pending regulatory approval.
Pricing Analysis
Current Market Price: In the U.S., the average wholesale price (AWP) is USD 7,500 per unit.
Reimbursement Rates: Medicare and private insurers reimburse at approximately 80% of AWP, translating to USD 6,000 per unit.
Price Trends: Price has increased 3% annually over the past five years due to inflation, manufacturing costs, and market demand.
Price Projections (Next 5 Years)
Year
Expected Price per Unit (USD)
Assumptions
Key Factors
2023
7,500
Current pricing
No significant market disruption
2024
7,725
3% inflation
Patent expiry approaches; slight increase in valuation
2025
5,500
Biosimilar/generic entry
Price reduction due to competition begins
2026
4,500
Continued biosimilar penetration
Market share shifts further downward
2027
3,500
Increased biosimilar adoption
Price stabilizes at a lower level
Market Risks and Opportunities
Patent expiry introduces pricing pressure and volume growth potential for generics.
Regulatory hurdles for biosimilar approval could delay market entry.
New indications or formulations could renew interest and pricing power.
Market entry of competitors with superior efficacy or lower costs could depress prices further.
Regulatory and Policy Impact
The FDA's follow-on biologic pathway could lower barriers for biosimilar approvals, impacting pricing from 2025 onward.
Price negotiation policies introduced in certain markets may cap reimbursement amounts, constraining revenues.
Strategic Considerations
R&D investment in next-generation formulations or indications could sustain premium pricing.
Licensing or partnership opportunities in emerging markets could expand access and volume.
Monitoring regulatory approvals and patent expirations is key for timing market entry and projections.
Key Takeaways
The drug's market is projected to decline in price from USD 7,500 to USD 3,500 per unit over five years, primarily due to biosimilar competition’s influence.
Market size remains robust, with growth driven by increasing demand and expanding regional access.
Competitive and regulatory risks could accelerate price declines but also present opportunities for early biosimilar adoption.
Strategic R&D and geographic expansion can offset downward pricing trends.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
